Active — Not RecruitingNot Applicable

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Japan1,024 participantsStarted 2024-10-22

Plain-language summary

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study. * Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment. Exclusion Criteria: * None

What they're measuring

Incidence of Adverse Drug Reactions (ADRs)

Timeframe: Up to 52 weeks

Trial details

NCT IDNCT06527846

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-03-31

View on ClinicalTrials.gov More Kidney Disease, Chronic trials